Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.74 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.74 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.74 |
| ▸ | ADRA2B known ✓ | P18089 | 1/20 | 0.74 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.74 |
| ▸ | CYSLTR1 | Q9Y271 | 3/20 | 0.74 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.74 |
| ▸ | CYSLTR2 | Q9NS75 | 2/20 | 0.74 |
| ▸ | MEN1 | O00255 | 1/20 | 0.74 |
| ▸ | RECQL | P46063 | 1/20 | 0.74 |
| ▸ | BLM | P54132 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.74 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.74 |
| ▸ | EGFR | P00533 | 1/20 | 0.74 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | PGR | P06401 | 1/20 | 0.74 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.74 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL1204496 | 1.00 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1204492 | 1.00 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL4540935 | 1.00 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL4540939 | 1.00 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1768658 | 1.00 | CYSLTR1 (0.74) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1592789 | 0.99 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL6111295 | 0.99 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1592793 | 0.99 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL6111115 | 0.99 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL | |
| Acetic Acid SCHEMBL1133382 | 0.99 | CYSLTR1 (0.73) | CYSLTR1CYP2C8CYSLTR2MEN1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2004608-B1 | AN IMPROVED PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LTD (IN) | 2011-09-14 | — | — | EP | claimed |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | HANMI PHARM. CO., LTD. (KR) | 2011-05-05 | — | — | US | claimed |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | GLADE ORGANICS PRIVATE LIMITED (IN) | 2009-11-12 | — | — | US | claimed |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CHAWLA HARMANDER SINGH PAL | 2009-07-16 | — | — | US | claimed |
| EP-1709001-A2 | SOLID FORMS OF MONTELUKAST ACID | Pliva Istrazivanje i Razvoj d.o.o. (HR) | 2006-10-11 | — | — | EP | claimed |
| WO-2005073194-A2 | SOLID FORMS OF MONTELUKAST ACID | PLIVA- ISTRAZIVANJE I RAZVOJ D.O.O. (HR) | 2005-08-11 | — | — | WO | claimed |
| EP-3222279-B1 | ORAL PHARMACEUTICAL FORMULATION OF MONTELUKAST AND LEVOCETIRIZINE AND METHOD FOR ITS PRODUCTION | INVEST BIELANY SPOLKA Z OGRANICZONA ODPOWIEDZIALNOSCIA (PL) | 2021-11-17 | — | — | EP | disclosed |
| EP-3397284-A1 | BILAYER TABLET FORMULATIONS OF MONTELUKAST AND RUPATADINE | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2018-11-07 | — | — | EP | disclosed |
| EP-3397285-A1 | TABLET FORMULATIONS OF MONTELUKAST SODIUM AND RUPATADINE FUMARATE | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2018-11-07 | — | — | EP | disclosed |
| WO-2017182644-A1 | TABLET FORMULATIONS OF MONTELUKAST SODIUM AND RUPATADINE FUMARATE | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2017-10-26 | — | — | WO | disclosed |
| WO-2017182641-A1 | BILAYER TABLET FORMULATIONS OF MONTELUKAST AND RUPATADINE | SANOVEL ILAC SANAYI VE TICARET A.S. (TR) | 2017-10-26 | — | — | WO | disclosed |
| EP-3222279-A1 | ORAL PHARMACEUTICAL FORMULATION OF MONTELUKAST AND LEVOCETIRIZINE AND METHOD FOR ITS PRODUCTION | Invest Bielany Spolky z Ograniczona Odpowiedzialnoscia (PL) | 2017-09-27 | — | — | EP | disclosed |
| EP-2949321-A1 | MULTILAYER FORMULATIONS OF FEXOFENADINE AND MONTELUKAST | Sanovel Ilac Sanayi ve Ticaret A.S. (TR) | 2015-12-02 | — | — | EP | disclosed |
| WO-2005105749-A2 | PROCESS FOR MAKING MONTELUKAST AND INTERMEDIATES THEREFOR | SYNTHON B.V. (NL) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | SYNTHON IP INC. | 2005-11-03 | — | — | US | disclosed |
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | SYNTHON BV (NL) | 2005-11-03 | — | — | US | disclosed |
| US-20050234241-A1 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (montelukast) and its pharmaceutically acceptable salts | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2005-10-20 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050107612-A1 | Process for preparation of montelukast and its salts | DR. REDDY'S LABORATORIES LIMITED | 2005-05-19 | — | — | US | disclosed |
| US-20050107426-A1 | Solid-state montelukast | SYNTHON BV (NL) | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245568-A1 | Process for making montelukast and intermediates therefor | CYP51A1, GPR17, CYP27A1 | ESR1 4615/4885ADRB2 1251/4885ADRA2A 2472/4885 |
| US-20050107612-A1 | Process for preparation of montelukast and its salts | MPST, CMA1, TPMT | ESR1 4253/4885ADRB2 1009/4885ADRA2A 1926/4885 |
| US-20090182148-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | AP1S1, CMA1, MED1 | ESR1 4830/4885ADRB2 333/4885ADRA2A 663/4885 |
| US-20050107426-A1 | Solid-state montelukast | CYSLTR1, CYSLTR2, LTA4H | ESR1 3537/4885ADRB2 674/4885ADRA2A 1414/4885 |
| US-20050245569-A1 | Process for making montelukast and intermediates therefor | LTA4H, CYP4A11, LTC4S | ESR1 4460/4885ADRB2 1280/4885ADRA2A 2481/4885 |
| US-20050234241-A1 | Process for the preparation of [R-(E)-1-[[[1-[3-[2-[7-chloro-2-quinolinyl]ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methyl]cyclopropaneacetic acid (montelukast) and its pharmaceutically acceptable salts | CMA1, HRH2, HRH1 | ESR1 3539/4885ADRB2 40/4885ADRA2A 57/4885 |
| US-20090281323-A1 | PROCESS FOR THE MANUFACTURE OF MONTELUKAST SODIUM | CMA1, MED1, MPST | ESR1 4562/4885ADRB2 549/4885ADRA2A 629/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | ESR1 547/4885ADRB2 392/4885ADRA2A 253/4885 |
| US-20110105757-A1 | METHOD FOR PREPARATION OF MONTELUKAST ACID IN IONIC LIQUID MEDIUM | CYSLTR1, LTC4S, CYSLTR2 | ESR1 4749/4885ADRB2 1827/4885ADRA2A 2264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.